section name header

Pronunciation

PRI-mi-done

Classifications

Therapeutic Classification: anticonvulsants

Indications

BEERS REMS


Unlabeled Use:
  • Essential (familial) tremor.

Action

  • Decreases neuronal excitability.
  • Increases the threshold of electric stimulation of the motor cortex.
Therapeutic effects:
  • Prevention of seizures.

Pharmacokinetics

Absorption: 80–100% absorbed from the GI tract when administered orally.

Distribution: Widely distributed to tissues

Metabolism/Excretion: Converted to phenobarbital and another active anticonvulsant compound by the liver.

Half-Life: 3–7 hr.

Time/Action Profile

(anticonvulsant effect)

ROUTEONSETPEAKDURATION
PO4–7 days7–10 days8–12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, orthostatic hypotension

Derm: alopecia, rash

EENT: visual changes

GI: anorexia, hepatitis, nausea, vomiting

Hemat: blood dyscrasias, folic acid deficiency, megaloblastic anemia

Neuro: ataxia, drowsiness, vertigo, excitement ( in children), SUICIDAL THOUGHTS

Resp: dyspnea

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Mysoline